News

Weill Cornell Researchers Improve Risk Assessment for Stable Patients with Suspected Heart Disease

Using basic information like age, gender and clinical history, Weill Cornell Medical College researchers have developed a simple method to more accurately predict whether a stable patient is likely to suffer from coronary artery disease or die of a heart attack in the next three years.

Cardiologists often use algorithms to determine whether or not patients should undergo invasive testing. With this easy-to-use, accurate method to determine risk, they can...

Weill Cornell Medical College and NewYork-Presbyterian Hospital to Introduce Electronic Informed Consent into its Cancer Clinics

Joint Clinical Trials Office Selects Mytrus’ Enroll® Platform for pilot project to enhance patient education and engagement in research studies

New York, New York and Davis, California (June 15, 2015) — The Joint Clinical Trials Office of Weill Cornell Medical College and NewYork-...

How patients can benefit from clinical trials

Monday, April 20, 2015 Fox News

Look online and you'll find endless ads for medical studies, trials, and surveys that pay. Some sites offer $5 just for signing up. Some travel studies pay $40, and clinical studies that promise $150 an hour. But can you get rich off of research studies? It's not likely, unless you're making a major commitment.

NASA pays $18,000 for its exercise study, but you have to lie in bed for 70 days.

Egg donors can...

Dr. Selina Chen-Kiang (photo credit: Carlos Rene Perez)

Researchers See Promise for Two New Therapies for Mantle Cell Lymphoma After Discovering Why Tumors Can Become Resistant to a Newly Approved Treatment

The medication was so effective in mantle cell lymphoma, an aggressive, incurable cancer, that the Food and Drug Administration named ibrutinib a "breakthrough" drug. The unprecedented response — 68 percent of patients went into partial or complete remission when they took it — gained the agent accelerated approval last November.

But the disease remains a challenge. Researchers, including those at Weill...

Joint Clinical Trials Office Presents Information Session at One-Year Anniversary

A unique collaborate enterprise was formed on January 1, 2013 between NewYork-Presbyterian and Weill Cornell Medical College to foster and advance clinical research.

The Joint Clinical Trials Office (JCTO) was formed to address the need to provide fully-integrated support to investigators involved in clinical research. The JCTO provides a platform for improving efficiencies by streamlining workflow and eliminating duplicative processes. The integrated unit is able to offer services...

Key study results on novel, chemotherapy-free treatment for chronic lymphocytic leukemia reported in New England Journal of Medicine by clinical researcher at Weill Cornell Medical College/NewYork-Presbyterian

Use of a twice-daily pill could turn a deadly blood cancer into a highly treatable disease, according to scientists at Weill Cornell Medical College (WCMC) and New York-Presbyterian (NYP) who led a multinational research team. Their findings on the therapy for chronic lymphocytic leukemia (CLL), reported in the Jan. 22 issue of the New England Journal of Medicine, suggest that patients may be able to avoid having to take debilitating chemotherapy.

NewYork-Presbyterian and Weill Cornell Medical College Launch New Institute of Cardiovascular Imaging to focus on research, clinical care and education

To help reduce the burden of cardiovascular disease, the nation's leading killer, NewYork-Presbyterian (NYP) and Weill Cornell Medical College (WCMC) have created the Dalio Institute of Cardiovascular Imaging. Raymond T. Dalio, a life trustee of NYP, has made a gift of $20 million through his Dalio Foundation in support of the institute.

The Dalio Institute of Cardiovascular Imaging will employ a multidisciplinary, multimodality approach to the detection and treatment of heart disease...

‹ previous
10 of 10